

Carlos Schönfeldt-Lecuona

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5816368/publications.pdf>

Version: 2024-02-01

70
papers

4,577
citations

304743

22
h-index

102487

66
g-index

78
all docs

78
docs citations

78
times ranked

5533
citing authors

#	ARTICLE	IF	CITATIONS
1	Evidence and expert consensus based German guidelines for the use of repetitive transcranial magnetic stimulation in depression. <i>World Journal of Biological Psychiatry</i> , 2022, 23, 327-348.	2.6	4
2	Incidence of inpatient cases with mental disorders due to use of cannabinoids in Germany: a nationwide evaluation. <i>European Journal of Public Health</i> , 2022, 32, 239-245.	0.3	7
3	Psychological Distress, Fear and Coping Strategies During the Second and Third Waves of the COVID-19 Pandemic in Southern Germany. <i>Frontiers in Psychiatry</i> , 2022, 13, 860683.	2.6	17
4	Arrhythmias related to antipsychotics and antidepressants: an analysis of the summaries of product characteristics of original products approved in Germany. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 767-775.	1.9	7
5	Factors related to age at depression onset: the role of SLC6A4 methylation, sex, exposure to stressful life events and personality in a sample of inpatients suffering from major depression. <i>BMC Psychiatry</i> , 2021, 21, 167.	2.6	16
6	Risk of Bleeding Associated with Antidepressant Drugs: The Competitive Impact of Antithrombotics in Quantitative Signal Detection. <i>Drugs - Real World Outcomes</i> , 2021, 8, 547-554.	1.6	3
7	Glial fibrillary acidic protein as blood biomarker for differential diagnosis and severity of major depressive disorder. <i>Journal of Psychiatric Research</i> , 2021, 144, 54-58.	3.1	34
8	Risk of Bleeding Associated With Antidepressants: Impact of Causality Assessment and Competition Bias on Signal Detection. <i>Frontiers in Psychiatry</i> , 2021, 12, 727687.	2.6	3
9	Plasminogen Activator Inhibitor "1 Serum level in patients with major depressive disorder vs. healthy controls: a systematic review and meta-analysis. <i>Trends in Psychiatry and Psychotherapy</i> , 2021, , .	0.8	1
10	Retinal single-layer analysis with optical coherence tomography (OCT) in schizophrenia spectrum disorder. <i>Schizophrenia Research</i> , 2020, 219, 5-12.	2.0	25
11	Treatment of the Neuroleptic Malignant Syndrome in International Therapy Guidelines: A Comparative Analysis. <i>Pharmacopsychiatry</i> , 2020, 53, 51-59.	3.3	18
12	Relation of Promoter Methylation of the Oxytocin Gene to Stressful Life Events and Depression Severity. <i>Journal of Molecular Neuroscience</i> , 2020, 70, 201-211.	2.3	17
13	Depressive Disorder With Panic Attacks After Replacement of an Intrauterine Device Containing Levonorgestrel: A Case Report. <i>Frontiers in Psychiatry</i> , 2020, 11, 561685.	2.6	5
14	The neuroleptic malignant syndrome—a systematic case series analysis focusing on therapy regimes and outcome. <i>Acta Psychiatrica Scandinavica</i> , 2020, 142, 233-241.	4.5	24
15	Depression, mitochondrial bioenergetics, and electroconvulsive therapy: a new approach towards personalized medicine in psychiatric treatment - a short review and current perspective. <i>Translational Psychiatry</i> , 2020, 10, 226.	4.8	22
16	Emotional Components of Pain Perception in Borderline Personality Disorder and Major Depression—A Repetitive Peripheral Magnetic Stimulation (rPMS) Study. <i>Brain Sciences</i> , 2020, 10, 905.	2.3	3
17	S-ketamine induces acute changes in the proteome of the mouse amygdala. <i>Journal of Proteomics</i> , 2020, 216, 103679.	2.4	6
18	Proteomic analysis reveals a biosignature of decreased synaptic protein in cerebrospinal fluid of major depressive disorder. <i>Translational Psychiatry</i> , 2020, 10, 144.	4.8	20

#	ARTICLE	IF	CITATIONS
19	Common Factors of Psychotherapy in Inpatients With Major Depressive Disorder: A Pilot Study. <i>Frontiers in Psychiatry</i> , 2019, 10, 463.	2.6	2
20	Neurofilament light chain as a blood biomarker to differentiate psychiatric disorders from behavioural variant frontotemporal dementia. <i>Journal of Psychiatric Research</i> , 2019, 113, 137-140.	3.1	81
21	Intranasal Pregabalin Administration: A Review of the Literature and the Worldwide Spontaneous Reporting System of Adverse Drug Reactions. <i>Brain Sciences</i> , 2019, 9, 322.	2.3	3
22	Psychiatrists' and dentists' knowledge and attitudes regarding adverse drug reactions of psychotropic drugs. <i>Psychiatry Research</i> , 2018, 266, 323-327.	3.3	2
23	Retinal changes in patients with major depressive disorder – A controlled optical coherence tomography study. <i>Journal of Affective Disorders</i> , 2018, 227, 665-671.	4.1	24
24	Response letter: Retinal changes in patients with major depressive disorder - a controlled optical coherence tomography study. <i>Journal of Affective Disorders</i> , 2018, 239, 123.	4.1	2
25	Major depressive disorder: insight into candidate cerebrospinal fluid protein biomarkers from proteomics studies. <i>Expert Review of Proteomics</i> , 2017, 14, 499-514.	3.0	26
26	Extending the aceruloplasminemia phenotype: NBIA on imaging and acanthocytosis, yet only minor neurological findings. <i>Journal of the Neurological Sciences</i> , 2017, 376, 151-152.	0.6	10
27	Drug safety and adverse drug reaction reporting behavior related to outpatient opioid replacement therapy: Results from a survey among physicians. <i>Journal of Substance Abuse Treatment</i> , 2017, 74, 7-15.	2.8	5
28	Brain activity to transitional objects in patients with borderline personality disorder. <i>Scientific Reports</i> , 2017, 7, 13121.	3.3	5
29	1-Hz rTMS in the treatment of tinnitus: A sham-controlled, randomized multicenter trial. <i>Brain Stimulation</i> , 2017, 10, 1112-1120.	1.6	38
30	EVIDENCE MAPS FOR DRUG THERAPY IN FRAIL OLDER ADULTS. <i>Innovation in Aging</i> , 2017, 1, 1321-1322.	0.1	0
31	Sensitivity of Quantitative Signal Detection in Regards to Pharmacological Neuroenhancement. <i>International Journal of Molecular Sciences</i> , 2017, 18, 101.	4.1	3
32	Successful Treatment of Major Depressive Disorder With Add-On Buprenorphine in a Patient With Previous Nonresponse to Standard Antidepressants. <i>primary care companion for CNS disorders</i> , The, 2017, 19, .	0.6	1
33	From Imaging the Brain to Imaging the Retina: Optical Coherence Tomography (OCT) in Schizophrenia. <i>Schizophrenia Bulletin</i> , 2016, 42, sbv073.	4.3	52
34	Non-Invasive Brain Stimulation in Conversion (Functional) Weakness and Paralysis: A Systematic Review and Future Perspectives. <i>Frontiers in Neuroscience</i> , 2016, 10, 140.	2.8	17
35	Drug-Induced Liver Injury Associated With Antidepressive Psychopharmacotherapy: An Explorative Assessment Based on Quantitative Signal Detection Using Different MedDRA Terms. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 769-778.	2.0	13
36	Subjective Reasons for Non-Reporting of Adverse Drug Reactions in a Sample of Physicians in Outpatient Care. <i>Pharmacopsychiatry</i> , 2016, 49, 57-61.	3.3	17

#	ARTICLE	IF	CITATIONS
37	Psychiatrische Notfälle im Notfall- und Rettungswesen. , 2016, , 29-42.		0
38	Risk of Bleeding Related to Selective and Non-selective Serotonergic Antidepressants: A Case/Non-case Approach Using Data from Two Pharmacovigilance Databases. Pharmacopsychiatry, 2015, 48, 19-24.	3.3	12
39	The neural correlates of movement intentions: A pilot study comparing hypnotic and simulated paralysis. Consciousness and Cognition, 2015, 35, 158-170.	1.5	8
40	Hepatotoxicity associated with agomelatine and other antidepressants: Disproportionality analysis using pooled pharmacovigilance data from the Uppsala Monitoring Centre. Journal of Clinical Pharmacology, 2015, 55, 768-773.	2.0	9
41	From benzodiazepine to pregabalin dependence: Different agents, similar problems. Indian Journal of Psychiatry, 2015, 57, 111.	0.7	6
42	Association between haemorrhages and treatment with selective and non-selective serotonergic antidepressants: Possible implications of quantitative signal detection. Psychiatry Research, 2015, 229, 257-263.	3.3	17
43	Risk of Bleeding Related to Selective and Non-selective Serotonergic Antidepressants: A Case/Non-case Approach Using Data from Two Pharmacovigilance Databases. Pharmacopsychiatry, 2015, 48, e1-e1.	3.3	0
44	Abuse liability of centrally acting non-opioid analgesics and muscle relaxants – a brief update based on a comparison of pharmacovigilance data and evidence from the literature. International Journal of Neuropsychopharmacology, 2014, 17, 957-959.	2.1	9
45	Rapid relapse in depression following initialization of oral contraception with ethinyl estradiol and chlormadinone acetate. General Hospital Psychiatry, 2014, 36, 230.e1-230.e2.	2.4	2
46	Abuse of methylphenidate in Germany: Data from spontaneous reports of adverse drug reactions. Psychiatry Research, 2014, 215, 252-254.	3.3	31
47	Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS). Clinical Neurophysiology, 2014, 125, 2150-2206.	1.5	1,647
48	Psychiatrische Notfallsituationen. , 2013, , 337-350.		0
49	Pregabalin-associated Elevation of Clozapine Serum Levels. Pharmacopsychiatry, 2012, 45, e2-e2.	3.3	0
50	Effect of 1ÂHz Repetitive Transcranial Magnetic Stimulation Over the Auditory Cortex on Audiometry and Otoacoustic Emissions. Brain Topography, 2012, 25, 241-247.	1.8	15
51	Liver failure under valproic acid. European Psychiatry, 2011, 26, 1282-1282.	0.2	0
52	Bone marrow, depression – transmission of psychiatric diseases through hematologic stem cell transplantation ? - Aetiologic considerations and a clinical case report. European Psychiatry, 2011, 26, 704-704.	0.2	0
53	Pain perception in borderline personality disorder explored using PMS. European Psychiatry, 2011, 26, 1003-1003.	0.2	1
54	Exploring the affective component of pain perception during aversive stimulation in borderline personality disorder. Psychiatry Research, 2011, 186, 458-460.	3.3	27

#	ARTICLE	IF	CITATIONS
55	Mechanisms and Applications of Theta-burst rTMS on the Human Motor Cortex. <i>Brain Topography</i> , 2010, 22, 294-306.	1.8	202
56	Transcranial magnetic stimulation in depression – Lessons from the multicentre trials. <i>Restorative Neurology and Neuroscience</i> , 2010, 28, 569-576.	0.7	33
57	The value of neuronavigated rTMS for the treatment of depression. <i>Neurophysiologie Clinique</i> , 2010, 40, 37-43.	2.2	64
58	Sham or real? Post hoc estimation of stimulation condition in a randomized transcranial magnetic stimulation trial. <i>Neuroscience Letters</i> , 2010, 471, 30-33.	2.1	35
59	Continuous theta-burst stimulation over the dorsal premotor cortex interferes with associative learning during object lifting. <i>Cortex</i> , 2009, 45, 473-482.	2.4	27
60	Antidepressant effects of augmentative transcranial magnetic stimulation. <i>British Journal of Psychiatry</i> , 2007, 191, 441-448.	2.8	174
61	Transcranial Magnetic Stimulation in Motor Conversion Disorder: A Short Case Series. <i>Journal of Clinical Neurophysiology</i> , 2006, 23, 473-476.	1.7	49
62	Investigating directed influences between activated brain areas in a motor-response task using fMRI. <i>Magnetic Resonance Imaging</i> , 2006, 24, 181-185.	1.8	95
63	Accuracy of Stereotaxic Positioning of Transcranial Magnetic Stimulation. <i>Brain Topography</i> , 2005, 17, 253-259.	1.8	84
64	Acute psychosis with a mediastinal carcinoma metastasis. <i>Medical Science Monitor</i> , 2005, 11, CS6-8.	1.1	4
65	Stereotaxic rTMS for the treatment of auditory hallucinations in schizophrenia. <i>NeuroReport</i> , 2004, 15, 1669-1673.	1.2	94
66	Using the International 10-20 EEG System for Positioning of Transcranial Magnetic Stimulation. <i>Brain Topography</i> , 2003, 16, 95-99.	1.8	848
67	Add-on rTMS for treatment of depression: a pilot study using stereotaxic coil-navigation according to PET data. <i>Journal of Psychiatric Research</i> , 2003, 37, 267-275.	3.1	112
68	Transcranial Magnetic Stimulation in the Reversal of Motor Conversion Disorder. <i>Psychotherapy and Psychosomatics</i> , 2003, 72, 286-288.	8.8	22
69	Intracortical excitability is modulated by a norepinephrine-reuptake inhibitor as measured with paired-pulse transcranial magnetic stimulation. <i>Psychopharmacology</i> , 2002, 164, 228-232.	3.1	54
70	Transcranial magnetic stimulation in therapy studies: examination of the reliability of –standard– coil positioning by neuronavigation. <i>Biological Psychiatry</i> , 2001, 50, 58-61.	1.3	330